Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381472 · ClinicalTrials.gov registry record · Phase 3
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
NCT00381472 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 393 participants.
The verdict
NCT00381472, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
Study Summary
The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa medication.
Interventions
- DRUG Ropinirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381472
The ClinicalTrials.gov registry entry for NCT00381472 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropinirole is the first listed.
NCT00381472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381472 about?
NCT00381472 is a clinical study titled "Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa". The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa medication.
What is the current status of trial NCT00381472?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2003-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00381472?
The interventions under investigation include: Ropinirole (DRUG).
Who is sponsoring clinical trial NCT00381472?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.